Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Testing policies probably effect the number of known cases. Duh...
Even in the USA where tests are openly available the number tested has dropped significantly. Many countries only test when symptons are seen or at the hospital stages.
Dr. fauci says vaccines are the answer but distribution is slow even in more advanced countries and many countries have almost no vaccine AND little testing..?. The dip in cases is going back up almost everywhere. ?.
https://ourworldindata.org/grapher/exports/covid-19-testing-policy.png?v=193
https://www.worldometers.info/coronavirus/covid-19-testing/
Testing policies probably effect the number of known cases. Even in the USA where tests are openly available the number tested has dropped significantly. Many countries only test when symptoms are seen or at the hospital stages.
Dr. fauci says vaccines are the answer but distribution is slow even in more advanced countries and many countries have almost no vaccine AND little testing..?. The dip in cases is going back up almost everywhere. ?.
https://ourworldindata.org/grapher/exports/covid-19-testing-policy.png?v=193
https://www.worldometers.info/coronavirus/covid-19-testing/
Thanks to all for the shared research and Opinions.
BUT HOW ABOUT SOME "IMO"s - 'POSSIBLY COULD' - 'I THINK HE SAYS' - 'THIS MIGHT MEAN' - 'MY OTHER RESEARCH SEEMS TO CONFIRMS'.
Investors don't run any of the companies. They can only Buy, Hold or Sell the stock preferably with some fore sight.
NRLA;NRLX:NRAX. Drop the P. OR RALF;RFLA. ASAP...GLTA...
O'quin joins Rem, rejected by the WHO...
“The panel considers that this drug is no longer a research priority and that resources should be used to evaluate other more promising drugs to prevent COVID-19,” the WHO said in a statement....
About time, wasted hospital patients lives and other possible treatment research...IMO
https://www.msn.com/en-us/health/medical/world-health-organization-advises-against-using-hydroxychloroquine-as-covid-19-treatment/ar-BB1eajPZ?ocid=msedgdhp
https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients
The WHO does not support use of the competition's drugs anymore.?.
“The panel considers that this drug is no longer a research priority and that resources should be used to evaluate other more promising drugs to prevent COVID-19,” the WHO said in a statement....
About time, wasted hospital patients lives and other possible treatment research...IMO
https://www.msn.com/en-us/health/medical/world-health-organization-advises-against-using-hydroxychloroquine-as-covid-19-treatment/ar-BB1eajPZ?ocid=msedgdhp
https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients
I sometimes wished he could put on a tie but his answers were mainly very sharp even while bopping around. Like Dr Nutt in a recent video, Dr MW took the hard questions and then answered them with very knowledgeable facts and opinions.
The Mad Scientist has AGN now with the DSMB approval to move Ifenprodil to Phase 3 AND with apparent 'Strong Trends' for analysis. I am hopeful for good Targets to be set for Ifenprodil's future path.?.
Dr Bryant and Dr.Khalil were involved with these Ifenprodil Trials so it seems continuity is good...GLTA...
" Since joining the Company on a full-time basis last year, Dr. Bryan has been managing its contract research providers and clinical trials, as well as all of its vendor relationships. He has also been managing the Company’s intellectual property suite.
Dr. Khalil has been acting for the last year as the Sponsor Medical Monitor for Algernon’s AGN120-1 and AGN120-3 clinical programs.
The USA and some other countries have had recent success in fighting COVID thru isolation, masks and social distancing. But the rest of the world has less testing yet more infections. Many comparative 'maps' at this site. Other good info.
Even the US has been lax recently with testing dropping 50% thru Feb. Many places World wide where only symptomatic patients are tested.
The isolated countries like SK, AUS, VN and even China have done the best.
https://ourworldindata.org/coronavirus-testing
In reply to your post Bartsdad
.Hmmmmm WHIST?
RLNXA, RLXA, RLAX.>>> drop the B(P).
The 28 day main signal seems to be Length of Stay ( P=.004). That is significant.
NRXP is running out of time. RLF probably wanted to wait for full 60day, IMO. NRX will probable file for EUA with that signal ASAP.
A supplemental EUA will probably be submitted with the EAP data for the patients too sick for the Placebo Trial. I hope.
NRX ran this COVID and we can see some bickering (?s) about the time lines. Probably why RLF got blindsided as JJ released SOME data instead of FULL data.
GEM has been a major financer for BOTH companies.
...GLTA...
Worth watching with some hints.
Dr Nutt is a sharp old Scientist. IMO. Kicked ass on the 'stumper' questions...
Strong demand for successful Stroke medications.
$2.5M in the bank suggests to me CM will wait till after Data for any PIPE/eu philanthropist's funding?
Pre clinical to be done by CRL / Finland. Trial too?.
...GLTA...
Russia and India (Japan, SK, Aus +) make their own decisions irrespective of USFDA decisions, IMO. Sounds like the CFO/Sales teams are prepping for those other markets besides the USA...GLTA...
30 patient Phase 1? No results on CT.gov
Adviptadil has the EAP program with hundreds of the sickest showing strong results along with Phase2/3 Data asap... Its a race to an EUA that RLF is winning, IMO...GLTYA...
With the wide secondary outcome in the Buc trial maybe we will also see the longer term healing effects that Thiols may provide and show additional uses for Buc treatment...
“It’s not that you get out of the hospital and you get completely better,” Ahmad said. “Not only that, 60% of these patients have persistent respiratory symptoms after three months, and 25% of the patients actually developed lung function abnormality after three months.”
https://www.winknews.com/2021/02/25/dealing-with-long-term-lung-damage-from-covid-19/
Ahhh X-rays of damaged lungs! hmmmm
“It’s not that you get out of the hospital and you get completely better,” Ahmad said. “Not only that, 60% of these patients have persistent respiratory symptoms after three months, and 25% of the patients actually developed lung function abnormality after three months.”
https://www.winknews.com/2021/02/25/dealing-with-long-term-lung-damage-from-covid-19/
“It’s not that you get out of the hospital and you get completely better,” Ahmad said. “Not only that, 60% of these patients have persistent respiratory symptoms after three months, and 25% of the patients actually developed lung function abnormality after three months.”
https://www.winknews.com/2021/02/25/dealing-with-long-term-lung-damage-from-covid-19/
AGN may work with Charles River Labs. The short Cramer clip talks about portions of the market they are involved in. Pretty good work by AGN CEO to get a foot in that door and a path set.
I posted the Rem results because it included how many sites just Rem would control. Times many from other big Pharma. It was sharp work to fill and complete the COVID Trial. IMO.
In the results (I) saw High P values and high adverse effects? Maybe someone qualified can relate their results to AGN expected results.
The inclusion of supplemental info and x-rays may support the decisions of primary and secondary outcomes for the now DSMB approved Phase 3 Trial. Adding ARDS and CC etc may be possible. A Covid after effect is lung damage. Maybe dosage thru longer lengths. I think CM has thought of many things.
IMO, most of these 'less' publicized PRs are directed at folks already following the RLF-100 story.
The Big news AND Follow-up will have GEM involved for guidance. That.s what they do besides pipes.
About The GEM Group:
Global Emerging Markets ("GEM") is a $3.4 billion alternative investment group based
in Paris, New York and Los Angeles. GEM manages a diverse set of investment vehicles
focused on emerging markets that provide the group and its investors with a diversified
portfolio of asset classes that span the global private investing spectrum. Each investment
vehicle has a different degree of operational control, risk-adjusted return and liquidity
profile. The family of funds and investment vehicles provide GEM and its partners with
exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities
(PIPEs) and select venture investments.
I have not looked at the OS / Float for a while and it appears stable. 3.2B / 1.23B. GEM holding means?
https://www.neurorxpharma.com/nrx.neurorxpharma.com/assets/10.23.19---press-release-neurorx-gem.pdf
CRL getting some time with Cramer. Looks like CM reeled in a great catch for DMT.
https://realmoney.thestreet.com/investing/stocks/look-for-the-rally-in-charles-river-labs-to-continue-15576983
BTW my runner up 'are you diversified'. Way back..T C Mo Oi Ba.
1/2009 Goog bought ont. First and best otc. At the time I was mad but held the shares...GLTA...
.SW is up 18%.
Ah yes, The 'JEWEL'
" Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.
NeuroRx is solely responsible for clinical development and regulatory submissions related to RLF-100™ in the U.S."
...GLTA...
28 day / secondary outcome is pretty broad in the Trial and faster healing due to less severe symptoms or thiol effects is possible, IMO. Maybe lung damage due to chronic cough would have been a better term than lung scaring.
A knockout success would be nice though...GLTA...
Will Buc be effective in healing scared lungs from COVID damage? Day 28 may show additional results besides helping fight the initial disease. First 120 patients may show some trends...GLTA...
Mammal virus transfer? Bat Soup! Dead cows from Covid?
Maybe suspend the IPF and get a partial refund used toward research for pre Phase 3 possibilities? I can dream.
Aren't ARDS and CC resulting symptoms from COVID? Certainly lung scaring. These will be the aftermath of COVID along with Kidney issues, CKD. Including a supplemental seems logical if there are some positive 28 day results as compared to 14 day trends...GLTA...
Rem was recruiting in SK. Criteria is no other drug except SoC. Their BP money blocked many from access to other possibly Trials. The Group of BP demand for Trial patients made/makes it to accomplish recruitment without a Big Brother/BP.
I can also dream that we will find one for to join in Ifenprodil Phase 3.
zWow, I grow good sh*t. 4:20. ALOHA. teddad
...GLTA...
I would hope the benefits of Ifenprodil that may be shown with the COVID Trial and then the supplemental lung scaring X rays / etc, may make some outcome points common and overlapping with IPF/ARDS/CC for the Phase 3. IDKS but hope they have some plan.
We're piss-ants. I hope Novatech isn't getting full pay for the failures in SK and now in Australia.
4838 patients X $25k = $121M. BP money. IPF was our Ifenprodil 'FDA Orphan drug' path before COVID. We beat Merck by 40%..GLTA...
Rem and the other BPs seem to have dominated recruiting patients around the world. Look at this list. BP money. Block out the spots at a lot of sites. Lucky we had a path to fill our Trial.
Rem had WHO scores as Outcomes but I barely see the positives in the results. Maybe some one can help explain it and compare this to our Trial's expected results. Is the high % of adverse effects a DSMB issue?...GLTA...
edit, are their P values good?
https://clinicaltrials.gov/ct2/history/NCT04292899?A=9&B=21&C=Side-by-Side#StudyPageTop
The biggest changes were here using the compare 'side by sides, 60 day change as secondary outcome with different endpoints. Some tweaking since.
https://clinicaltrials.gov/ct2/history/NCT04311697?A=15&B=16&C=Side-by-Side#StudyPageTop
A look at Rem results. They stayed with the WHO scale and had <12% effect in the randomized evaluations for 397 of 4800 total patients. Look at all the Sites they took, world wide CASH / BP has influence. Also TEAEs seem high.
https://clinicaltrials.gov/ct2/history/NCT04292899?A=9&B=21&C=Side-by-Side#StudyPageTop
My opinion too in answer to TM. With 1.6B float there are alot of traders, oh well. This news will be around and I hope for it to influence many in the coming days and weeks...GLTA...
Yep, couldn't add @$.34 this AM after the supposed 'hit piece' but got a bunch @<$.4 and am now helping push this with 1ks to $.49. So far.
I still see some strong reasons for NRX to write a deal regarding the Formulation Patent at RLF. RLF-100 is proving to be the 'JEWEL'. GEM will control things at both. This appears to be the Real start. JMHO...GLTA...
Yea I dont get med's continued efforts here.
I totally respect ALL Cops* and Veterans, those Drafted from my generation and All Volunteers. All Cops are volunteers.
Like Stocks, others make most of the decisions we live with. I'm drinking/thinking. Thanking God for letting my brother and niece survive COVID.
I was truly disappointed at the Lack of a Global Unified response to COVID. When will we Learn?
war?
https://www.bing.com/videos/search?q=youtube+lee+michaels+song+war&docid=608039414230681376&mid=27EE1940D9433001DD9827EE1940D9433001DD98&view=detail&FORM=VIRE
*
Yes Kal too, he was another reason I first bought into BLO @$.50.
Ive smelled Asian dirt and walked among the trees and paddies.
yes you've made it clear @ both message boards about how you think the companies should have been ran and with always complaining about the 'sister's' pps moves compared to this. I dont get that either. Certainly about Kal's other Board positions/favoritism and failures.
I'm sure Cm / MW / Kal/ almost everyone wanted the knockout punch for Ifenprodil. Even med gives credit for the successful efforts.
One guy calls me out for faked pumping, another for bashing and I'm used to another's posturing / agenda(?). Thanks to All for Respecting My opinions...LOL...
...GLTA...
My understanding is that the DSMB will stop a Trial for 'futility' or negative results at Phase 2, especially safety.
I rambled and was replying to another Shareholder's accusations and comments...GLTY Sir on your future investments...
We've had this discussion before. Some dont ever (?) trade, I did in both and did well with BLO. Plenty of volume there. $.07 to the $.20 @ BTH is still a profit. I was into the FAIMS technologies back then for breath thru that Dr Yost demise and the L3 buyout of imsc, where I learned about it and these stocks... Say POT legalization hype/spike.
Kal's an X Drug Cop so BLO was his 'favorite' and may still do OK. Sorry you missed out.(?). I have a few shares left...
The 7M++ shares traded/stopped after the PR disaster in Dec were certainly not all Kal's. He's Not the devil.
The only real volume was provided by another poster's Buying during the Dec wait for data. I didnt see capitulation and most investors apparently will wait. Yes, people make risky investments in a speculative OTC stock. WS/LS...OMG...
DSMB said continue the COVID trial to Phase 3 with no 'safety' or 'futility' issues. THEY seem to think there is possible benefit and no harm. Phase 3 Primary and Secondary outcomes/endpoints will be determined after full Phase 2 data.
Your agenda and comments are past my understanding. My posts wont disappear and as seen by the volume of posts here, your opinions are a dominant part of the record. Other investors are risking their money and accusations of corruption are free speech 'until'...GLTA...
The cost of All those lessons, Hot Chicks (and stocks/weather/fishing/opinions+++) = Toxicity.
We are a small company and would be kaput as BTH if not for the redirection to repurposed drugs. Dr MW found research and a reasonable path to target lung issues with ifenprodil. COVID enhanced the effort. Many discussed the proposed science.
The CT was not the knock-out we all had a hope for. Some were smart enough to 'stoploss'. Many including me missed that chance. A bad reactive PR didnt help the early result of a change to the WHO score for patients. Really too few patients for more than a trend.?.
Management did not say it would be the Bomb, but that ifenprodil may prove effective in some ways in the COVID battle. The H5N1 results as compared against other CC drugs showed promise, not knockouts. We all would appreciate info about ANY other drug showing a knockout punch at COVID.
Lots of Real Hype and disinformation with mildly successful (even Bad) results from all/anything else beyond SOC. On hindsight we all were wrong expecting that knockout and for not planning for less spectacular results.
All attempts to Treat COVID have basically been a 'Flop' no matter if it was Big Pharma or pumped by the highest 'bully pulpit'. Extreme EFFORTS by compassionate Nurses and Doctors under great Risk has been the most successful by far.
Early discussions here were of Ifenprodil joining in as a 'cocktail' Treatment. That is the bar and has been / will be until some treatments show stronger successes. JMHO...GLTA...
DrE, I read your post twice, Thanks for the effort.
PFE still @$35 a year into COVID and with Billions of waiting vaccine customers. Selling the peaks and dips with no real pps appreciation. Too big to succeed? flippers? wow.
At AGN we have some strong prospects IMO. No revenues but a possibility of success for the company to complete their stated agenda of bringing a repurposed drug to Market. Yes most possibly as a buyout item, IMO. Then on to the next. Possible EUA is what I think we are trying to achieve for Ifenprodil, not mass long term production.
Plenty of wine and complaints of missing opportunities in other stocks due to someone else's acumen/flipping/attention/action. BLO and AGN/BTH have had their times and IMO will again.
Another opine is that Excessive Bloviating directed at any opinions and all posts may harm credibility, shooting one's own foot affects the group here.
Yes, lung recovery is the current target as part of a COVID treatment or for CC/IPF or long haulers. Plans for a future after COVID are important for a repurposed drug company...GLTA...
.
Then this,
"WHO ordinal scores are not a good endpoint for COVID trials. I think when we see the results of the final data analysis from the ifenprodil Phase 2, the value is going to be in all of the other endpoints. If there is a signal in decreasing time to ventilation, this could get EUA and the company will hit the jackpot."
Now this...
From the veranda I see some at the whinery are pissing on the Vines, AFTER partaking of the hospitalities and having had opinions respected...
Ive had many occasions where I had to wait for the last cards due to the size of the pot. WS/LS. Bluffing (?) fine. Selling stocks for a profit, sure.
Great BLO $ gambled at BTH.? Thanks Kal.
BUT. Kicking the table on purpose when others are still seated, Fkn Sad. Seeing a bunch of whinoes on this OTC...GLWT...
There's probably a 'gansta' video. But I'm an old cpl.
Fleetwood mac, Oh well;
When I talk to God I hope he understands
It's stick by me Ill be a guiding hand
but dont ask me what I Think of you
I might not give the answer that you want me to...
https://www.bing.com/videos/search?q=fleetwood+mac+oh+well&view=detail&mid=4C8644FCCFDD58F8CAB04C8644FCCFDD58F8CAB0&FORM=VIRE0&ru=%2fsearch%3fq%3dfleetwood%2bmac%2boh%2bwell%26form%3dANNTH1%26refig%3dd0a10913a3f349dfbe682893771d7eea%26sp%3d1%26ghc%3d1%26qs%3dSC%26pq%3dfleetwood%2bmac%252C%2bohwell%26sk%3dPRES1%26sc%3d8-21%26cvid%3dd0a10913a3f349dfbe682893771d7eea
How about this?
Primary Outcome change from ARDS to Respiratory Failure, Start / Completion date etc for Inhaler Trial.
NRX again trying to show their leadership? Mention of RLF - 100 formulation as the Drug etc the same. Who's paying for the Trial, RLF or NRX.?.
Is the Data for the IV Trial officially locked and in processing / independent review?
https://clinicaltrials.gov/ct2/history/NCT04360096?A=4&B=5&C=Side-by-Side#StudyPageTop
Algernon, thru some connection or whatever GOT A FOOT IN THE DOOR OF THE "Charles River Labs Inc" (CLR) and are legitimately planning and being ACCEPTED by CLR. Sure not a done deal yet, but getting attention from CLR seems a BFD to Me...GLTA...
M42CRF- Final Rule / SAP? Lots of significant changes since NRX took over. and early interim unblinding? Trial Power calculations? Pathetic release of TLD...GLTA...
JJ needs rights for use of the patent for RLF 100 formulations in the NRXP deal for HIS company.
Must have been allowed and they are obviously going to try and use this in support of the primary goal. Apparently the sickest may have benefited most. There may be an associated delay to reprocess the data presentation. A GOOD presentation and PLAN is Needed after the First Data fiasco.?.
I still question how NRX and RLF will resolve the Patent issue along with the 3.2B OS used to finance the Trials...GLTA...
https://clinicaltrials.gov/ct2/history/NCT04311697?A=19&B=20&C=Side-by-Side#StudyPageTop
Orphan Disease Designation like IPF?
About IPF
Idiopathic pulmonary fibrosis, an orphan disease, is a type of chronic lung condition characterized by a progressive and irreversible decline in lung function and scarring (fibrosis) of the lungs. There is no cure for IPF and there are currently no procedures or medications that can remove the scarring from the lungs.
https://www.globenewswire.com/news-release/2019/07/03/1877782/0/en/Algernon-Pharmaceuticals-NP-120-Reduced-Fibrosis-in-an-Idiopathic-Pulmonary-Fibrosis-Study-by-56-Outperforming-USFDA-Approved-Treatments-Nintedanib-and-Pirfenidone.html
Where/ Why/ When AGN/ Ifenprodil started...GLTA...
GEM thru RLF shareholders paid for the CT and the RLF-100 patent for formulations of VIP which is at Relief, and it was managed some by NRX as agreed in part of the revenue share agreement and to bring DrJJ supposed expertise into managing the medical side. GEM also financed NRX-100/101 pre COVID but that trial was delayed.
Pissing match and finger pointing continues due to endpoint / WHO unrealistic initial goals. Early Data for the EAP near death patients was lost in the CT values for the moderate CT and confusing endpoints.
Pathetic managing of data releases did not help. What company gets blame or benefits and how will Nasdaq Moves happen is my concern now. NRXP? RLFAC? Combo? FUBAR????!!!????
I Guess GEM is pissed about This AFU situation and institutional investors NOT involved. I was...GLTA...